Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors
Ruprecht Nitschke(University of Oklahoma Health Sciences Center), Stuart Toledano(Children's Hospital of Philadelphia), Jeffrey P. Krischer(University of South Florida), Willem A. Kamps(Pediatric Oncology Group), Teresa J. Vietti, Holcombe E. Grier(Harvard University), Charles B. Pratt(St. Jude Children's Research Hospital), Michael B. Harris(Icahn School of Medicine at Mount Sinai)
Cited by 5
Related Papers
Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association
|Diabetes Care|2015|1.2k
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
|New England Journal of Medicine|2011|1.1k
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
|The Lancet Oncology|2009|932